Associate Professor in Cancer Immunology – Department of Biotherapeutics Research (DBR)
Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University, invites applications for the post of Associate Professor in Cancer Immunology under its Department of Biotherapeutics Research (DBR). Applications are welcome from Indian nationals, Persons of Indian Origin (PIOs), Overseas Citizens of India (OCIs), and foreign nationals.
The Department of Biotherapeutics Research serves as a premier interdisciplinary research hub working on cell, gene, protein, 3D bioprinting, and nano/biomaterials-based therapies. This position provides an exceptional opportunity for immunology and oncology researchers with a strong publication and grantsmanship record to lead independent research, secure extramural funding, build biopharma partnerships, and mentor junior scientists.
Application Instructions: Eligible candidates must send a detailed application comprising a cover letter, curriculum vitae, contact details of three referees, copies of relevant certificates, and other supporting documents merged into a single PDF file on or before August 15, 2026. The subject line of the email must clearly state: “Faculty Position – DBR, MAHE, Manipal”. Applications can also be sent by postal mode to the Director – HR office.
PhD in Immunology, Tumor Biology, Molecular Oncology, or a closely related field, with First Class or equivalent in the preceding degree and a consistent academic record.
Minimum of 7 years of teaching, research, or industrial experience (excluding PhD duration).
Must have published at least six manuscripts in Q1 journals as a first or corresponding author post-PhD.
Eligible categories: Indian nationals, PIOs, OCIs, and foreign nationals.
Hands-on expertise in immunological assays, tumor microenvironment studies, checkpoint inhibition, CAR-T cell therapy, and cancer biotherapeutics development.
Proven track record of securing extramural research funding.
Postdoctoral research experience from a reputed foreign institution in cancer immunology (highly desirable).
Preferred experience working in Biosafety Level 2/3 (BSL2/BSL3) facilities.
Preferred exposure to preclinical cancer models and immunoprofiling.
Preferred background in industry collaborations and translational research outputs, such as patents or licensed technologies.
Demonstrated leadership in team science, research project execution, and academic mentoring.
As per MAHE norms (commensurate with qualification and experience)
August 15, 2026